GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immunovant Inc (NAS:IMVT) » Definitions » LT-Debt-to-Total-Asset

IMVT (Immunovant) LT-Debt-to-Total-Asset : 0.00 (As of Dec. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Immunovant LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Immunovant's long-term debt to total assests ratio for the quarter that ended in Dec. 2024 was 0.00.

Immunovant's long-term debt to total assets ratio stayed the same from Dec. 2023 (0.00) to Dec. 2024 (0.00).

Immunovant LT-Debt-to-Total-Asset Historical Data

The historical data trend for Immunovant's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immunovant LT-Debt-to-Total-Asset Chart

Immunovant Annual Data
Trend Dec18 Mar20 Mar21 Mar22 Mar23 Mar24
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial - 0.01 - - -

Immunovant Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Immunovant LT-Debt-to-Total-Asset Calculation

Immunovant's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Mar. 2024 is calculated as

LT Debt to Total Assets (A: Mar. 2024 )=Long-Term Debt & Capital Lease Obligation (A: Mar. 2024 )/Total Assets (A: Mar. 2024 )
=0/666.365
=

Immunovant's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (Q: Dec. 2024 )=Long-Term Debt & Capital Lease Obligation (Q: Dec. 2024 )/Total Assets (Q: Dec. 2024 )
=0/420.932
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Immunovant  (NAS:IMVT) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Immunovant LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Immunovant's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Immunovant Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immunovant Inc (NAS:IMVT) » Definitions » LT-Debt-to-Total-Asset
Comparable Companies
RXRX SRRK RNA BHVN ZLAB ADMA CRNX ACLX RYTM APLS VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX XBRU:UCB ALNY ONC BNTX XKRX:068270
Traded in Other Exchanges
N/A
Address
320 West 37th Street, 6th Floor, New York, NY, USA, 10018
Website
https://www.immunovant.com
Immunovant Inc is a clinical-stage biopharmaceutical company. It is focused on enabling normal lives for patients with autoimmune diseases. The company's product includes batoclimab and IMVT-1402 targets the neonatal Fc receptor (FcRn).
Executives
Andrew J. Fromkin director C/O RADIUS HEALTH, INC., 201 BROADWAY, 6TH FL, CAMBRIDGE MA 02139
William L. Macias officer: Chief Medical Officer C/O IMMUNOVANT, INC., 320 WEST 37TH STREET, 6TH FLOOR, NEW YORK NY 10018
Eva Renee Barnett officer: Chief Financial Officer C/O IMMUNOVANT, INC., 320 WEST 37TH STREET, 6TH FLOOR, NEW YORK NY 10018
Peter Salzmann director, officer: Chief Executive Officer 320 W 37TH STREET, 3RD FLOOR, NEW YORK NY 10016
Jay S Stout officer: Chief Technology Officer C/O VERSARTIS, INC., 4200 BOHANNON DR., SUITE 250, MENLO PARK CA 94025
Roivant Sciences Ltd. 10 percent owner CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11
Atul Pande director C/O AXOVANT SCIENCES, INC., 1441 BROADWAY, 3RD FLOOR, NEW YORK NY 10018
Douglas J. Hughes director C/O EARGO, INC., 2665 NORTH FIRST STREET, SUITE 300, SAN JOSE CA 95134
Mark S. Levine officer: Chief Legal Officer 1601 TRAPELO ROAD, SUITE 284, WALTHAM MA 02451
Julia G. Butchko officer: Chief Dev. & Tech. Officer 320 W 37TH STREET, 3RD FLOOR, NEW YORK NY 10016
George V Migausky director C/O DYAX CORP., 300 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Frank Torti director 2855 SAND HILL ROAD, MENLO PARK CA 94025
Rita Jain officer: Chief Medical Officer C/O AKEBIA THERAPEUTICS, INC., 245 FIRST STREET, SUITE 1100, CAMBRIDGE MA 02142
Michael James Elliott officer: Chief Scientific Officer 320 WEST 37TH STREET, NEW YORK NY 10018
Eric Venker director C/O ROIVANT SCIENCES, INC., 320 WEST 37TH STREET, 6TH FLOOR, NEW YORK NY 10018